A citation-based method for searching scientific literature

Carol Aghajanian, Stephanie V Blank, Barbara A Goff, Patricia L Judson, Michael G Teneriello, Amreen Husain, Mika A Sovak, Jing Yi, Lawrence R Nycum. J Clin Oncol 2012
Times Cited: 781



Timothy J Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A Ledermann, Eric Pujade-Lauraine, Gunnar Kristensen, Mark S Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédéric Selle, Mansoor R Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh K B Parmar, Amit M Oza. N Engl J Med 2011
Times Cited: 1197




List of shared articles



Times cited

A prospective cohort study on the safety and efficacy of bevacizumab combined with chemotherapy in Japanese patients with relapsed ovarian, fallopian tube or primary peritoneal cancer.
Yoshiko Nanki, Hiroyuki Nomura, Naomi Iwasa, Keiko Saotome, Ai Dozen, Tomoko Yoshihama, Takuro Hirano, Shiho Hashimoto, Tatsuyuki Chiyoda, Wataru Yamagami,[...]. Jpn J Clin Oncol 2021
1

Management of ovarian cancer: guidelines of the Italian Medical Oncology Association (AIOM).
Angiolo Gadducci, Giovanni D Aletti, Fabio Landoni, Roberta Lazzari, Giorgia Mangili, Paola Olivas, Sandro Pignata, Vanda Salutari, Enrico Sartori, Giovanni Scambia,[...]. Tumori 2021
1

Bevacizumab-associated events in Japanese women with cervical cancer: a multi-institutional survey of Obstetrical Gynecological Society of Kinki district, Japan.
Seiji Mabuchi, Misa Yamamoto, Hiroko Murata, Takuya Yokoe, Junzo Hamanishi, Yoshito Terai, Hikaru Imatake, Yasushi Mabuchi, Taisuke Mori, Fuminori Kitada,[...]. Int J Clin Oncol 2021
1

SEOM clinical guideline in ovarian cancer (2020).
A Redondo, E Guerra, L Manso, C Martin-Lorente, J Martinez-Garcia, J A Perez-Fidalgo, M Q Varela, M J Rubio, M P Barretina-Ginesta, A Gonzalez-Martin. Clin Transl Oncol 2021
1

The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Shiru Liu, Lawrence Kasherman, Rouhi Fazelzad, Lisa Wang, Genevieve Bouchard-Fortier, Stephanie Lheureux, Monika K Krzyzanowska. Gynecol Oncol 2021
1

Stiffness increases with myofibroblast content and collagen density in mesenchymal high grade serous ovarian cancer.
Virginie Mieulet, Camille Garnier, Yann Kieffer, Thomas Guilbert, Fariba Nemati, Elisabetta Marangoni, Gilles Renault, Foucauld Chamming's, Anne Vincent-Salomon, Fatima Mechta-Grigoriou. Sci Rep 2021
2

REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Katrin M Sjoquist, David Espinoza, Linda Mileshkin, Sumitra Ananda, Catherine Shannon, Sonia Yip, Jeffrey Goh, David Bowtell, Michelle Harrison, Michael L Friedlander. Gynecol Oncol 2021
2

Poly(ADP-ribose) polymerase inhibitors in combination with anti-angiogenic agents for the treatment of advanced ovarian cancer.
Olivia Le Saux, Hélène Vanacker, Fatma Guermazi, Mélodie Carbonnaux, Clémence Roméo, Louis Larrouquère, Olivier Trédan, Isabelle Ray-Coquard. Future Oncol 2021
0

PARP Inhibitor in Platinum-Resistant Ovarian Cancer: Single-Center Real-World Experience.
Amit Agarwal, Saphalta Baghmar, Chandragouda Dodagoudar, Suhail Qureshi, Aseem Khurana, Vikas Vaibhav, Guresh Kumar. JCO Glob Oncol 2021
0

Bevacizumab, carboplatin, and paclitaxel in the first line treatment of advanced ovarian cancer patients: the phase IV MITO-16A/MaNGO-OV2A study.
Gennaro Daniele, Francesco Raspagliesi, Giovanni Scambia, Carmela Pisano, Nicoletta Colombo, Simona Frezzini, Germana Tognon, Grazia Artioli, Angiolo Gadducci, Rossella Lauria,[...]. Int J Gynecol Cancer 2021
3

A randomized phase II/III trial of conventional paclitaxel and carboplatin with or without bevacizumab versus dose-dense paclitaxel and carboplatin with or without bevacizumab, in stage IVB, recurrent, or persistent cervical carcinoma (JCOG1311): Primary analysis.
Mitsuya Ishikawa, Taro Shibata, Takashi Iwata, Shin Nishio, Toshio Takada, Shiro Suzuki, Koji Horie, Wataru Kudaka, Masahiro Kagabu, Michihiro Tanikawa,[...]. Gynecol Oncol 2021
1

Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
Angeles Alvarez Secord, David M O'Malley, Anil K Sood, Shannon N Westin, Joyce F Liu. Gynecol Oncol 2021
0

Bevacizumab in First-Line Chemotherapy Improves Progression-Free Survival for Advanced Ovarian Clear Cell Carcinoma.
Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Yuki Shiko, Yoshihito Ozawa, Yohei Kawasaki, Makio Shozu. Cancers (Basel) 2021
0


Retrospective analysis of the role of cyclin E1 overexpression as a predictive marker for the efficacy of bevacizumab in platinum-sensitive recurrent ovarian cancer.
Adriana Regina Gonçalves Ribeiro, Marcella Marineli Salvadori, Louise de Brot, Graziele Bovolin, Henrique Mantoan, Felipe Ilelis, Mariana Rezende, Nayra Soares do Amaral, Solange Moraes Sanches, Joyce Maria Lisboa Maya,[...]. Ecancermedicalscience 2021
0

Adjuvant and post-surgical treatment in high-grade epithelial ovarian cancer.
Georgina E Wood, Jonathan A Ledermann. Best Pract Res Clin Obstet Gynaecol 2021
0

Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Sandro Pignata, Domenica Lorusso, Florence Joly, Ciro Gallo, Nicoletta Colombo, Cristiana Sessa, Aristotelis Bamias, Vanda Salutari, Frédèric Selle, Simona Frezzini,[...]. Lancet Oncol 2021
11

Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial.
J A Ledermann, A C Embleton-Thirsk, T J Perren, G C Jayson, G J S Rustin, S B Kaye, H Hirte, A Oza, M Vaughan, M Friedlander,[...]. ESMO Open 2021
1

Correlation of imaging and plasma based biomarkers to predict response to bevacizumab in epithelial ovarian cancer (EOC).
Megan E Buechel, Danielle Enserro, Robert A Burger, Mark F Brady, Katrina Wade, Angeles Alvarez Secord, Andrew B Nixon, Seyedehnafiseh Mirniaharikandehei, Hong Liu, Bin Zheng,[...]. Gynecol Oncol 2021
0

Real-world experience of olaparib as maintenance therapy in BRCA-mutated recurrent ovarian cancer.
Angela Cho, Jeong-Yeol Park, Shin-Wha Lee, Dae-Yeon Kim, Dae-Shik Suh, Jong-Hyeok Kim, Yong-Man Kim, Young-Tak Kim. Arch Gynecol Obstet 2021
0

Risk stratification model based on VEGF and International Prognostic Index accurately identifies low-risk diffuse large B-cell lymphoma patients in the rituximab era.
Wei Sang, Hang Zhou, Yuanyuan Qin, Ziyuan Shen, Dongmei Yan, Cai Sun, Xuguang Song, Yuhan Ma, Dongyun Tu, Zhenzhen Bian,[...]. Int J Hematol 2021
0

Bevacizumab in advanced endometrial cancer.
Maria M Rubinstein, Shannan Dickinson, Priyanka Narayan, Qin Zhou, Alexia Iasonos, Weining Ma, Yulia Lakhman, Vicky Makker. Gynecol Oncol 2021
1

Programmed death ligand-1 regulates angiogenesis and metastasis by participating in the c-JUN/VEGFR2 signaling axis in ovarian cancer.
Yufei Yang, Lingfang Xia, Yong Wu, Hongyu Zhou, Xin Chen, Haoran Li, Midie Xu, Zihao Qi, Ziliang Wang, Huizhen Sun,[...]. Cancer Commun (Lond) 2021
5

A CLEARER VIEW ON OVARIAN CLEAR CELL CARCINOMA.
Aglaja De Pauw, Eline Naert, Koen Van de Vijver, Tummers Philippe, Katrien Vandecasteele, Hannelore Denys. Acta Clin Belg 2021
0

Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients.
Pratik P Patil, Ranga R Rangaraju, Waseem Abbas, Sunny Garg. South Asian J Cancer 2021
0

Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer.
Isabelle Ray-Coquard, David Cibula, Mansoor R Mirza, Alexander Reuss, Caterina Ricci, Nicoletta Colombo, Horst Koch, Frédéric Goffin, Antonio González-Martin, Petronella B Ottevanger,[...]. Int J Cancer 2020
8

Overview of imaging findings associated with systemic therapies in advanced epithelial ovarian cancer.
Ezgi Guler, Daniel A Smith, Bhanusupriya Somarouthu, Rahul Gujrathi, Nikhil H Ramaiya, Sree Harsha Tirumani. Abdom Radiol (NY) 2020
2

Targeted therapy clinical trials in ovarian cancer: improved outcomes by gene mutation screening.
Quan Guo, Qing Yang, Jun Li, Guipeng Liu, Igor Nikoulin, Steve Jia. Anticancer Drugs 2020
3

Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Carolyn E Haunschild, Krishnansu S Tewari. Future Oncol 2020
10

Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218.
Angeles Alvarez Secord, Kirsten Bell Burdett, Kouros Owzar, David Tritchler, Alexander B Sibley, Yingmiao Liu, Mark D Starr, J Chris Brady, Heather A Lankes, Herbert I Hurwitz,[...]. Clin Cancer Res 2020
10

Pazopanib and Fosbretabulin in recurrent ovarian cancer (PAZOFOS): A multi-centre, phase 1b and open-label, randomised phase 2 trial.
Robert D Morgan, Susana Banerjee, Marcia Hall, Andrew R Clamp, Cong Zhou, Jurjees Hasan, Cecilia Orbegoso, Sarah Taylor, Jonathan Tugwood, Alexander R Lyon,[...]. Gynecol Oncol 2020
1

Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial.
Robert L Coleman, Katelyn F Handley, Robert Burger, Graziela Zibetti Dal Molin, Robert Stagg, Anil K Sood, Kathleen N Moore. Gynecol Oncol 2020
9

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lucy Gilbert, Ignace Vergote, Lainie P Martin, Gina M Mantia-Smaldone, Antonio González Martin, Raquel Bratos,[...]. Gynecol Oncol 2020
23

Ovarian cancer treatment is evolving: more choices, more chances.
Claudia Marchetti, Giovanni Scambia, Alessia Romito, Anna Fagotti. Int J Gynecol Cancer 2020
0


Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.
Josep Garcia, Herbert I Hurwitz, Alan B Sandler, David Miles, Robert L Coleman, Regula Deurloo, Olivier L Chinot. Cancer Treat Rev 2020
113

Recurrent Treatment in Ovarian Cancer Patients: What Are the Best Regimens and the Order They Should Be Given?
Joanna Glajzer, Jacek P Grabowski, Jalid Sehouli, Jacobus Pfisterer. Curr Treat Options Oncol 2020
1

Tolerability and Efficacy of Bevacizumab Monotherapy in Older Patients With Recurrent Ovarian Cancer.
Daisuke Shintani, Hiroyuki Yoshida, Akira Yabuno, Keiichi Fujiwara. In Vivo 2020
0

Bevacizumab-related gastrointestinal perforation in patients with three or more prior chemotherapy regimens: A real-world experience.
Hiroko Matsumiya, Yukiharu Todo, Hiroyuki Yamazaki, Chisa Shimada, Shinichiro Minobe, Hidenori Kato. Taiwan J Obstet Gynecol 2020
1

Cathepsin D in the Tumor Microenvironment of Breast and Ovarian Cancers.
Zahidul I Pranjol, Jacqueline L Whatmore. Adv Exp Med Biol 2020
5

Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy.
Kosuke Murakami, Yasushi Kotani, Hidekatsu Nakai, Noriomi Matsumura. Cancers (Basel) 2020
9